To evaluate and investigate the particular processes through which ACTA2, FLNA, TAGLN, and TPM1 contribute to the progression of BLCA, more in vitro and in vivo investigations and clinical samples are required. This evidence concerns the gene FLNA and bladder transitional cell carcinoma.